Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04648202 · ClinicalTrials.gov registry record · Phase 1
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
A Phase 1 study of Advanced Cancer and Metastatic Cancer, sponsored by invoX Pharma Limited.
- Active
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 9
- Study locations
NCT04648202 is a Phase 1 study of Advanced Cancer and Metastatic Cancer that is active but no longer recruiting, run by invoX Pharma Limited. The registered enrollment target is 82 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (67% lower). The trial reports 9 study locations across 4 states.
The verdict
NCT04648202, a Phase 1 study of Advanced Cancer and Metastatic Cancer, is active but no longer recruiting, sponsored by invoX Pharma Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
Conditions Studied
Interventions
- DRUG FS120
Study Locations (9)
Other
- NEXT Oncology, Hospital Quironsalud Barcelona - Barcelona
- Hospital Universitario Vall d'Hebron - Barcelona
- Hospital Universitario Fundacion Jimenez Diaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Clinico Universitario de Valencia - Valencia
Texas
- MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Connecticut
- Yale University - New Haven
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-11-18 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04648202
The ClinicalTrials.gov registry entry for NCT04648202 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (67% lower). The listed sponsor is invoX Pharma Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which FS120 is the first listed.
NCT04648202 reports 9 study locations spanning 4 distinct geographic areas - top geographies include Other, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04648202 about?
NCT04648202 is a clinical study titled "FS120 Phase 1/1b Study in Patients With Advanced Malignancies". This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
What is the current status of trial NCT04648202?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2020-11-18. Estimated completion is 2026-03-01.
What conditions does trial NCT04648202 study?
This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT04648202?
The interventions under investigation include: FS120 (DRUG).
Who is sponsoring clinical trial NCT04648202?
This trial is sponsored by invoX Pharma Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04648202 being conducted?
This trial has 9 study locations across Connecticut, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.